Skip to main content

Lactobacillus rhamnosus gg/omega-3 polyunsaturated fatty acids Disease Interactions

There are 3 disease interactions with lactobacillus rhamnosus gg / omega-3 polyunsaturated fatty acids.

Moderate

Omega-3 fatty acids (applies to lactobacillus rhamnosus gg/omega-3 polyunsaturated fatty acids) arrhythmias

Moderate Potential Hazard, Moderate plausibility.

Cases of recurrent atrial fibrillation (AF) or flutter have been reported with the use of omega-3 fatty acids in patients with a symptomatic paroxysmal AF or persistent AF. This condition is more apparent within the first 2 to 3 months after the initiation of therapy. Therapy with these agents should be administered cautiously in patients with cardiac conduction disorders.

Moderate

Omega-3 fatty acids (applies to lactobacillus rhamnosus gg/omega-3 polyunsaturated fatty acids) liver disease

Moderate Potential Hazard, Moderate plausibility.

Increases in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels have been observed in patients receiving omega-3 fatty acids. Therapy with omega-3 fatty acid preparations should be administered cautiously in patients with hepatic impairment. Serum liver enzyme levels should be monitored periodically.

Moderate

Probiotics (applies to lactobacillus rhamnosus gg/omega-3 polyunsaturated fatty acids) immunosuppression

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency

Probiotics, especially those containing lactobacillus, should be used with caution in immunosuppressed patients.

Switch to professional interaction data

Lactobacillus rhamnosus gg/omega-3 polyunsaturated fatty acids drug interactions

There are 421 drug interactions with lactobacillus rhamnosus gg / omega-3 polyunsaturated fatty acids.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer